	Application Number		10562246	
INFORMATION PIOCE COURT	Filing Date		2003-06-24	
INFORMATION DISCLOSURE	First Named Inventor	Steph	nen John Martin Skinner	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit			
(Not for Submission ander or of K 1.00)	Examiner Name			
	Attorney Docket Number		36697.16	

U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1	6716246		2004-04	I-06	Gonzalez					
If you wish to add additional U.S. Patent citation information please click the Add button. Add											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1										
If you wis	h to ac	dd additional U.S. Publis	shed Ap	plication	ı citatior	ո information բ	lease click the Add	button	Add		
				FOREIC	3N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	or -	vhere Rel	or Relevant	T5
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10562246
Filing Date		2003-06-24
First Named Inventor Steph		en John Martin Skinner
Art Unit		
Examiner Name		
Attorney Docket Number		36697.16

1	SELAWRY et al., "Sertoli Cell-Induced Effects on Functional and Structural Characteristics of Isolated Neonatal Porcine Islets," Cell Transplantation, 5(5):517-524, 1996.	
2	SUAREZ-PINZON et al, "Testicular Sertoli Cells Protect Islet B-Cells From Autoimmune Destruction in NOD Mice by a Transforming Growth Factor B1-Dependent Mechanism," Diabetes, 49:1810-1818, 2000.	
3	SUN et al., "Porcine Pancreatic Islets: Isolation, Microencapsulation and Xenotransplantation," Artificial Organs, 17 (8):727-33 1993.	
4	SUN et al., "Normalization of Diabetes in Spontaneously Diabetic Cynomologus Monkeys by Xenografts of Microencapsulated Porcine Islets without Immunosuppression," J. Clin. Invest., 98(6):1417-1422, 1996.	
5	WALTER et al., "Distinct Sites of Insulin-Like Growth Factor (IGF)-II Expression and Localization in Lesioned Rat Brain: Possible Roles of IGF Binding Proteins (IGFBPs) in the Mediation of IGF-II Activity," Endocrinology, 140(I) 520-532, 1999.	
6	WANG et al., "Protective Effects of Glial Cells Line-Derived Neurotrphic Factor in Ischemic Brain Injury," Ann. N.Y. Acad. Sci., 962: 423-437, 2002.	
7	WEBER et al., "Evaluation of Graft-Host Response for Various Tissue Sources and Animal Models," Ann. N.Y. Acad. Sci., 875:233-254, 1999.	
8	WEISS, "Xenografts and Retroviruses," Science, 285:1221-1222, 1999.	
9	ZHANG et al., "Migration and Differentiation of Adult Rat Subventricular Zone Progenitor Cells Transplanted into the Adult Rat Striatum," Neuroscience, 116:373-382, 2003.	
10	Examination Report to Australian Application No. 2002211122, June 10, 2005	
11	Examination Report to EP Application No. 00 925 757.7; October 29, 2003	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10562246
Filing Date		2003-06-24
First Named Inventor Steph		en John Martin Skinner
Art Unit		
Examiner Name		
Attorney Docket Number		36697.16

	12	Examination Report to EP Application No. 01 942 558.6; February 24, 2004						
	13	International Examination Report, Application No. PCT/NZ01/00228; December 16, 2002						
	14 International Search Report, Application No. PCT/NZ00/00064; November 28, 2000							
	15	International Search Report, Application No. PCT/NZ01/00006; April 26, 2001						
	16	International Search Report, Application No. PCT/NZ01/00228; March 11, 2002						
	17	International Search Report, Application No. PCT/NZ02/00235; February 21, 2003						
	18							
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10562246
Filing Date		2003-06-24
First Named Inventor Steph		en John Martin Skinner
Art Unit		
Examiner Name		
Attorney Docket Number		36697.16

Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):						
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).						
OF	₹						
	foreign patent of after making rea any individual d	information contained in the information diffice in a counterpart foreign application, an isonable inquiry, no item of information contaesignated in 37 CFR 1.56(c) more than thr 37 CFR 1.97(e)(2).	d, to the knowledge of the ained in the information dis	e person signing the certification sclosure statement was known to			
	See attached ce	rtification statement.					
	Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.						
X	None						
۸,	ianatura of the an	SIGNAT		9 Diagra see CER 1 4/d) for the			
1	A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.						
Sig	nature	/Mark D. Moore/	Date (YYYY-MM-DD)	2007-01-17			
Nar	ne/Print	Mark D. Moore, Ph.D.	Registration Number	42903			
pub 1.14	This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you						

require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria**,

CERTIFICATION STATEMENT

VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.